NCT01605253View on ClinicalTrials.gov

Eszopiclone for the Treatment of Posttraumatic Stress Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Posttraumatic Stress Disorders
Interventions
DRUG

Eszopiclone

Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.

DRUG

Placebo

The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.

Trial Locations (1)

60612

Center for Anxiety and Traumatic Stress Disorders at Rush, Chicago

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Rush University Medical Center

OTHER

NCT01605253 - Eszopiclone for the Treatment of Posttraumatic Stress Disorder | Biotech Hunter | Biotech Hunter